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Abstract: Breast cancer in young women is relatively rare compared to breast cancer occurring
in older women. Younger women diagnosed with breast cancer also tend to have a more aggressive
biology and consequently a poorer prognosis than older women. In addition, they face unique
challenges such as diminished fertility from premature ovarian failure, extended survivorship
periods and its attendant problems, and the psychosocial impact of diagnosis, while still raising
families. It is therefore imperative to recognize the unique issues that younger women face,
and plan management in a multidisciplinary fashion to optimize clinical outcomes. This paper
discusses the challenges of breast cancer management for young women, as well as specific
issues to consider in diagnosis, treatment, and follow-up of such patients.
Keywords: breast cancer, young women, diagnosis, treatment

Introduction
Early-onset breast cancer is relatively rare; however, it represents the commonest cause
of cancer in women under age the of 40.1 In the US, approximately 33,000 women under
the age of 45 years are diagnosed with breast cancer every year, and it is the leading
cause of cancer-related deaths in this age group.2 Compared to older women with
breast cancer, younger women tend to have a more aggressive biology and a poorer
prognosis (Table 1). Younger women with breast cancer also face unique challenges
such as premature ovarian failure, psychosocial issues with ongoing careers, and
raising young families, as well as extended survivorship periods and its attendant
complications as summarized in Figure 1. It is therefore imperative to recognize the
unique issues that younger women face and plan management in a multidisciplinary
fashion to optimize clinical outcomes.

Breast cancer screening
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Screening for breast cancer should begin at age 40 for average-risk women.3 This
includes annual mammography and clinical breast examination (CBE). Breast selfexamination (BSE) is an additional option. For average-risk women under age 40,
screening consists of CBE every 3 years with optional BSE; routine use of imaging
is not recommended. Although no studies have documented improved breast cancerrelated outcomes with BSE, given that routine imaging is not warranted, most malignancies in women under 40 will be detected by patients.4 Even for young women who
do undergo annual mammography, cancers that develop are more likely to present as
interval cancers.5–7 For this reason as well, CBE and BSE remain important screening
modalities for young women. Increased breast density seen in younger women lowers
1
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Table 1 Breast cancer features in younger patients
Incidence

More common in older women. 4.5% incidence
in women age ,40138

Presentation

More advanced in younger women, more
diagnostic delays10,11
High frequency of HR-negative disease29
As younger women are more likely to have
inherited susceptibility, genetic testing is
recommended for all patients #40 years
Inferior outcome in younger patients45,57,58
Premature ovarian failure, reduced fertility,
increased social stressors from raising young
children and active workforce participation,
prolonged survivorship period, bone loss

Biology
Genetics

Prognosis
Unique considerations

Abbreviation: HR, hormone receptor.

the sensitivity of mammography.8 Despite this, mammography is still an important screening tool. The incorporation
of tomosynthesis, or three-dimensional mammography, will
likely improve the sensitivity and specificity of mammography in women with dense breast tissue.9

Diagnostic evaluation of young
women with breast complaints
Women, regardless of age, who present with symptoms,
require diagnostic evaluation and a CBE. Because younger
women do not undergo routine screening mammography,
most will present with symptomatic and higher stage

Depression

breast cancer10,11 versus women diagnosed with a screening
study. Young age and symptomatic presentation are both
associated with delay in diagnosis and worse outcomes.10–12
The imaging modality selected for the diagnostic workup
depends on the patient’s age and presenting symptoms.13–16
Masses should be evaluated by ultrasound with or without
mammography, depending on the patient’s age, the clinical
suspicion, and the nature of the mass. Pathologic nipple
discharge concerning for ductal carcinoma in situ may
mandate mammography even in younger women to evaluate for calcifications. Magnetic resonance (MR) is typically
not indicated for evaluation of mammographic or ultrasound
abnormalities; suspicious findings on conventional imaging
or examination require standard evaluation, including biopsy,
even in the setting of a negative MR. Negative imaging of
any type does not negate the possibility of malignancy, and
therefore even in the setting of normal imaging, suspicious
palpable findings require biopsy for definitive diagnosis.

Genetic predisposition
First-degree relatives of women with breast cancer have
nearly a twofold increased breast cancer risk compared to the
general population, and this risk is much higher when the relative is diagnosed at a young age.17,18 Large twin studies have
demonstrated nearly one-third of all breast cancer is attributed
to hereditary factors.19,20 However, the susceptibility genes

Weight gain
Late cardiovascular effects

Hot flashes/night sweats

Chronic fatigue
Cognitive
dysfunction

Breast cancer
treatments in young
women
Reduced productivity

Premature ovarian failure
sexual dysfunction
Other 2nd-malignancy
(ie, endometrial cancer)

Arthralgia/joint symptoms
Osteoporosis/
bone fractures

Figure 1 Breast cancer diagnosis and treatment effects on young women.
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identified to date account for only 20%–30% of the excess
familial risk.21,22 Consequently, the genetic etiology for the
majority of families with an increased familial breast cancer
risk remains unknown.
Young age at diagnosis is a feature of hereditary disease,
and it is currently recommended that all women diagnosed
with breast cancer less than 40 years of age be referred for
genetics assessment. A higher proportion of young women
with breast cancer have germline mutations, compared to
their older counterparts, with most studies evaluating the
prevalence of BRCA1, BRCA2, and TP53 mutations.23–25
Furthermore, a greater proportion of young women, especially black women, have triple-negative disease, and among
these women there is also an increased frequency of germline
mutations, notably in BRCA1, BRCA2, and PALB2 genes.26
Identification of germline mutations has the potential to
impact a woman’s medical care, and to be informative for
at-risk family members.
Multiple gene panels, with concurrent analysis of genes
with varied levels of breast cancer risk, are now commonly
used in clinical practice. Maxwell et al27 evaluated the use
of a 22-gene panel among a cohort of young women with
breast cancer, classifying the results into clinically actionable
and unclear actionability, based on the available data of the
risks associated with each gene. Only 2.5% of this cohort of
278 patients was identified with clinically actionable gene
variants compared to 8.6% of patients with variants for which
clinical data are deficient.27 The current lack of clinical validity for many genes makes translating clinical genetic testing
results into improved patient care difficult, with the potential
for overtreatment. Some investigators have advocated that
genetic testing for breast cancer risk should only be offered
after the clinical validity is established for the genes to be
analyzed.28 Until additional cancer susceptibility genes are
discovered and clinical validation of recently discovered
genes is performed, clinicians will need to continue to rely on
the family cancer history to help guide medical care for the
majority of young women diagnosed with breast cancer.

Biology of early-onset breast cancer
Differences in pathologic characteristics between younger and
older women with breast cancers have been observed in multiple studies. The Prospective study of Outcomes in Sporadic
and Hereditary breast cancer is the largest to investigate factors affecting breast cancer prognosis in patients #40 years;
however, there is no comparison to older women due to the
observational nature of the study.29 Although only 30% of
the patients had screen-detected cancers, 50% of the patients
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in this multicenter study presented with nodal involvement.
One-third of them were hormone receptor (HR) negative,
20% had triple-negative breast cancer, and almost 60% had
poorly differentiated tumors. In addition, although majority
of patients received chemotherapy in addition to endocrine
therapy, 10% of those with HR-positive breast cancer developed a late relapse between years 5 and 8. At a median
follow-up of 5 years, the overall survival was 82%, with the
majority of deaths due to breast cancer. Another large study
using the California Cancer Registry also found that 20% of
adolescents and young adults with breast cancer had triplenegative disease and 54% had high-grade tumors.30 Numerous
other studies have also suggested more biologically aggressive
cancers in younger women.10,31–37
Gene expression profiling has subdivided triple-negativebreast cancer (TNBC) patients into clinically relevant
subtypes now being used to design clinical trials. 38
A comprehensive study on TNBC samples revealed several
biomarkers, including TP53, PIK3CA, AKT1, PTEN, and
HER2 mutations that may be therapeutically relevant in
the future.39 Clinical trials investigating agents targeted at
such aberrations are underway. For example, a recent openlabel Phase II trial investigating enzalutamide, an androgen
receptor (AR) antagonist, in AR-positive advanced TNBC
patients, reported a 16-week clinical benefit rate of 35%.40
TNBC cases that were strongly AR-positive exhibited lower
proliferation rates than those that were not AR-positive.39
These AR-positive tumors tend to be rich in genes regulated
by the hormonal pathway.
TNBC is an immunogenic form of breast cancer due to
the frequency of mutations causing neoantigens, and the association between high rates of tumor infiltrating lymphocytes
and improved response to chemotherapy and survival seen
in that subset of breast cancer.41,42 Novel immune checkpoint
inhibitors, such as the PDL1 and PD1 inhibitors, appear to
have activity in TNBC patients as well. Two studies utilizing
these agents in the advanced TNBC setting reported durable
clinical benefits in patients with PDL1-positive TNBC.43,44
Thus, new predictive markers in TNBC may prove to be
therapeutically relevant in the future.
Several groups have also found gene expression profile
differences between breast cancers occurring in younger versus older women. In the largest study evaluating age-related
biological differences in breast cancer, Azim et al45 found that
genes enriched in processes related to immature mammary
cell populations (RANKL, c-kit, BRCA1, mammary stem
cells, and luminal progenitors cells) and growth factor signaling (MAPK, PI3K) were predominant in younger women.
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Analysis of clinically annotated microarray data
from 784 breast cancer patients also revealed that young
women #45 years had lower mRNA expression of ERα,
ERβ, and PR, but higher expression of HER2 and EGFR as
opposed to women $65 years.46 In women ,40 years, gene
expression profiling further showed lower expression of ERα
and ERβ compared with women 40–50 years. In addition,
gene sets unique to younger women included those related
to biologically relevant and potentially actionable processes
such as immune function, mTOR/rapamycin pathway,
hypoxia, BRCA1, stem cells, apoptosis, histone deacetylase,
and multiple oncogenic signaling pathways.
Differences in biology in young women also differ
by race. In a large Surveillance, Epidemiology, and End
Result (SEER) study involving over 126,000 women
aged #49 years with breast cancer, we have previously
reported that a higher proportion of blacks versus whites
developed breast cancer under age 40. A higher proportion
of blacks also presented with HR negative, more advanced
stage, and higher grade tumors.47 In the Carolina Breast
Cancer Study, the prevalence of basal-like breast cancer was
highest (39%) among black premenopausal women compared
with other groups of patients (14%–16%).48 This has also
been observed in other studies in the US.49,50

Prognosis
A recent study showed an increase in the incidence of young
women aged 25–39 years diagnosed with metastatic breast
cancer from 1.53 to 2.90 per 100,000 from 1976 to 2009.51
Several reasons such as stage migration, improved surveillance, and population-based changes in breast cancer risk
factors may be implicated. This increase is particularly concerning as young age is an independent adverse factor for
poor prognosis among women with breast cancer.1,52–56 The
clinical outcome is worsened for very young women under
age 35, with the hazard of death increasing by every 1 year
decrease in age.57 It is also apparent that the effect of age on
outcome is modified by breast cancer subtype. A study by
Sheridan et al58 showed that within the HR-positive subtype,
younger age carried a worse prognosis than older age. This has
also been confirmed in Azim et al’s45 study, where they found
an inferior relapse-free survival with young age in the HRpositive/HER2-negative subtype in a subgroup analysis.

Treatment
Locoregional treatment – surgery
Young women with breast cancer have similar surgical
options as older women. These include breast conserva-
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tion therapy (BCT) (partial mastectomy with radiation) or
mastectomy. Although young age at diagnosis is associated
with a higher risk of local recurrence and more aggressive
phenotypes, data suggest no survival gains with mastectomy
compared to BCT, and there does not appear to be a survival advantage with contralateral prophylactic mastectomy
either.59–63 Therefore, young age alone is not a contraindication to BCT. Despite this, bilateral mastectomies are on the
rise in women of all ages.61–63 This is likely due to patient
and physician perception of improved outcomes and due to
improved reconstruction techniques and cosmesis. Immediate and immediate-delayed reconstruction are now preferred,
and many women are candidates for nipple sparing procedures with immediate or immediate-delayed reconstruction.
Nipple sparing procedures are increasingly being offered as
data supports the oncologic safety, and these procedures are
associated with better self-image.64,65

Locoregional treatment – radiotherapy
After partial mastectomy, adjuvant whole breast radiation
has been shown to reduce the risk of ipsilateral breast tumor
recurrence, as well as improve breast cancer survival.66,67
Adjuvant radiation is especially important for young women
in this setting, as their absolute risk of local recurrence is
higher than for older women, and as a result, younger women
have a greater absolute benefit from adjuvant radiation.67
For young women with early-stage breast cancer, there are
important considerations with regards to treatment volume.
Accelerated partial breast irradiation (APBI) may not be an
appropriate option for young women. Although results from
the NSABP B-39 trial,68 comparing whole and partial breast
radiation, are pending, there are several published consensus
statements describing APBI selection criteria. All include a
minimum patient age in their criteria, ranging from 45 to
60 years as the suggested minimum age.69–71 This is based
on the existing published literature on APBI which primarily includes women over 50, the concern for increased risk
of multifocal and multicentric disease in younger women,
and the known higher local recurrence rates seen in young
women who receive whole breast radiation. NSABP B-39
trial included women over 18 years old, and we await the
results from this trial.
Other considerations with regards to dose and fractionation include the use of boost and hypofractionation. In the
European Organization for Research and Treatment of Cancer
trial, use of boost reduced the 20-year cumulative incidence
of ipsilateral breast tumor recurrence from 16.4% to 12.0%
(hazard ratio: 0.65, P,0.0001).72 The benefit of a boost
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was found to be greatest for young women. The absolute
risk reduction was 4.4% in the entire cohort, and 11.6% for
women under 40. Hypofractionated whole-breast schedules
have been found to be as effective as standard fractionation
for certain populations. However, majority of these data
were obtained in women over 50 years old, and therefore
the American Society for Radiation Oncology guidelines on
fractionation support the use of hypofractionation only for
women over 50, who also meet the other specified criteria.73
Until further evidence is available for younger women, the
standard of care for these women includes delivery of wholebreast radiation with standard fractionation.
For women with locally advanced breast cancer, randomized trials have demonstrated a locoregional recurrence and
survival benefit to postmastectomy radiation for women
with large primary tumors .5 cm, invasion of the skin or
chest wall, or lymph node involvement.74–76 Retrospective
analysis of 107 stage II or III patients aged #35 years treated
with or without adjuvant radiation following mastectomy
showed that patients who received postmastectomy radiation compared with those who did not had a better 5-year
local control and overall survival rates.77 Since young age
and/or premenopausal status are risk factors for locoregional
recurrence after mastectomy, some young women with node
negative disease may benefit from postmastectomy radiation
if they have additional risk factors.78–80
For most breast cancer scenarios, young women have a
higher risk of local and regional recurrence, and therefore
derive an even greater absolute benefit from adjuvant radiation than older women. Given their young age and potential
for long-term survival, special care must be taken during
radiation treatment planning to minimize radiation exposure
to adjacent organs in order to reduce the risk of late effects
and secondary malignancies.

Systemic treatment – endocrine
The Early Breast Cancer Trialists’ Collaborative Group’s
(EBCTCG) meta-analyses demonstrated that 5 years of
adjuvant tamoxifen improved the annual breast cancer death
rate by one-third and recurrence risk by 50% for all women
with HR-positive cancers irrespective of age.81 However,
approximately 10% of those with HR-positive cancers will
develop a late relapse beyond year 5; therefore, there has
been interest in extending adjuvant endocrine therapy to
prevent later relapses. In the Adjuvant Tamoxifen: Longer
Against Shorter trial, women with early stage breast cancer
were randomly assigned to continue tamoxifen to 10 years
or stop at 5.82 Allocation to 10 years was associated with
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reductions in the risk of recurrence, improvements in breast
cancer specific survival, and overall survival. Similarly, in
the UK adjuvant Tamoxifen-To offer more? trial, 10 years
of adjuvant tamoxifen reduced late breast cancer recurrences
and mortality among women with HR-positive cancers.83
The group that continued tamoxifen to year 10 had further
reductions in recurrence, from year 7 onward, as well as
breast cancer mortality after year 10. Based on these and
other studies, the American Society for Clinical Oncology
clinical practice guideline now recommends treatment with
adjuvant tamoxifen for 10 years in women with stage I–III
HR-positive cancers. While these results were not restricted
to young women, in clinical practice, young patients who
are believed to have a worse prognosis are generally being
considered for 10 rather than 5 years of tamoxifen.
An alternative form of endocrine manipulation involves
ovarian suppression (OS). Although, the prognosis for premenopausal women who have chemotherapy-induced amenorrhea (CIA) is better than for those who do not have CIA, the
prognostic value of therapeutic OS remains unclear.84–86 The
Suppression of Ovarian Function (SOFT) trial was designed
to determine the utility of dual endocrine blockade by adding OS to tamoxifen and also to determine the benefit of an
aromatase inhibitor with OS for premenopausal patients.87
Premenopausal women were assigned to either 5 years of
tamoxifen, tamoxifen plus OS, or exemestane plus OS. At
5 years, 90.9% of those who received exemestane with OS
were free from breast cancer, versus 88.4% in the tamoxifen
plus OS arm, versus 86.4% in the tamoxifen alone group. In
the subgroup of women younger than 35 years, the rate of
freedom from breast cancer at 5 years was 83.4% for those
assigned to exemestane plus OS, 78.9% for those assigned
to tamoxifen plus OS, and 67.7% for patients assigned to
tamoxifen alone. Similarly, the Tamoxifen and Exemestane
Trial (TEXT) was designed to compare exemestane plus OS
versus tamoxifen plus OS also in premenopausal women.88
In the combined analysis of both SOFT and TEXT trials,
the 5-year rate of freedom from breast cancer was 92.8%
in those receiving exemestane plus OS, versus 88.8% for
those assigned to receive tamoxifen plus OS. The symptom
burden of OS with either tamoxifen or exemestane is higher
than tamoxifen alone and different depending on what drug
is given in combination with OS. Patients who receive
tamoxifen have more vasomotor symptoms, while those who
receive exemestane have more arthralgia, sexual dysfunction,
and vaginal dryness.89 These side effects need to be discussed
with individual patients prior to electing treatment. Results
from these studies show that even in premenopausal women
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with early stage breast cancer, the outcomes in those with HRpositive cancers is very good in general; however, there is still
a need to define who merits more aggressive therapy. In addition, further tools and research are needed on compliance,
management of menopausal symptoms, bone loss, cognitive
problems, and sexual dysfunction, and careful monitoring of
late side effects such as secondary malignancies.

Systemic treatment – chemotherapy
The preferred chemotherapy regimens remain the same for
all patients with early stage breast cancer irrespective of
age. In general, for most high-risk breast cancer patients,
combination regimens including anthracyclines and taxanes
are employed. The EBCTCG meta-analyses, evaluated the
benefits of adjuvant polychemotherapy on outcomes in
younger versus older women.81 Anthracycline-based chemotherapy combinations had a larger impact in reducing
the annual breast cancer death rate for women younger than
50 years (38% reduction) versus 20% for those aged 50–69
years. In addition, there was also a threefold age-related
benefit for polychemotherapy versus no chemotherapy for
women ,50 years versus women 50–69 years with larger
benefits for recurrences than mortality. The 5-year improvements from chemotherapy were approximately twofold for
HR-negative versus HR-positive cancers, but the 15-year
improvements were less dependent on HR status, likely due to
differences in timing of recurrences with HR-negative versus
HR-positive cancers. Preferred National Comprehensive Cancer Network (NCCN) guidelines for adjuvant chemotherapy
for high-risk HR-breast cancer patients include several regimens such as doxorubicin plus cyclophosphamide followed
by paclitaxel or docetaxel plus cyclophosphamide.

Systemic treatment – biologic therapy
Patients who have HER2+ breast cancer receive trastuzumab
as part of their (neo)adjuvant systemic treatment based on
improvements in overall survival seen in large randomized
trials.90–93 Young patients also derive similar benefits from
adjuvant trastuzumab as older patients.12 Pertuzumab is a
humanized monoclonal antibody directed at HER2 and is
approved in combination with trastuzumab and chemotherapy for treatment of HER2+ breast cancers in the neoadjuvant
and advanced settings based on several studies.94–96

Unique considerations
Fertility preservation
Among the unique concerns for young women with breast
cancer are treatment-induced ovarian failure and infertility.
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The risk of infertility varies according to age, reproductive
reserve, chemotherapy agent, duration of treatment, and dose
administered.97 Alkylating agents are among those with the
highest gonadotoxic properties.98 The true rates of infertility
after breast cancer treatments have been difficult to ascertain as there is no consensus on what constitutes infertility.
Different surrogates used in different studies include amenorrhea, estradiol, anti-Mullerian hormone, inhibin B, and
follicle count.99,100
Young women who are desirous of future childbearing
should be properly counseled by an oncofertility specialist
on options for fertility preservation prior to chemotherapy.
Existing reproductive options include embryo and oocyte
cryopreservation, cryopreservation of ovarian tissue, or
OS with luteinizing hormone releasing hormone (LHRH)
agonists.101–103 The POEMS study randomized 257 premenopausal women with HR-negative breast cancer to
receive standard chemotherapy with or without goserelin to
determine if goserelin reduced ovarian failure.104 The ovarian
failure rate was 8% in the intervention group versus 22% in
the chemotherapy group. In addition, 22 patients in the goserelin group achieved at least 1 pregnancy versus 12 in the
standard group, although more women in the goserelin group
attempted pregnancy. While these data are encouraging, the
use in those with HR-positive cancer is cautioned, as this
study only included those with HR-negative cancer. Although
less of an issue with LHRH agonists that are administered
during chemotherapy, practical barriers limiting fertility
preservation are cost, insurance, absence of a male partner,
and chemotherapy timing issues.
Retrospective studies have suggested no worsening
of breast cancer outcomes in patients who become
pregnant.105–108 POSITIVE (Pregnancy Outcome and Safety
of Interrupting Therapy for women with endocrine responsIVE Breast Cancer) is an ongoing trial, designed to evaluate
the safety and outcomes of women with HR-positive cancers
who interrupt endocrine therapy for childbearing. This trial
seeks to enroll women under age 42 who have received
18–30 months of endocrine therapy and who then stop endocrine therapy temporarily to attempt pregnancy.109 Guidelines
also recommend avoiding pregnancy within 6 months of
systemic therapy completion, due to teratogenicity.110,111

Pregnancy-associated breast cancer
The incidence of pregnancy at the time of breast cancer diagnosis is approximately 1.5%, and breast cancer is the most
common pregnancy-associated malignancy in women.112–114
A confirmed diagnosis of malignancy should prompt
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due to the longer life expectancy. One particular area which
has received a lot of recent attention is bone health. Although
fragility fractures are more common in women over 50 years,
several factors lead to bone compromise in younger women
treated for breast cancer. Androgens and estrogens are regulators of bone growth, and consequently, estrogen deficiency
is a key determinant in bone loss. Cancer treatments with
chemotherapy can lead to estrogen deficiency via gonadal
dysfunction, and also impair bone health via direct effects
on bone metabolism or systemic steroids commonly used
as supportive medications during chemotherapy. Radiation
can impair bone integrity in the treated radiation field.
Hormonal treatment designed to induce hypogonadism also
leads to accelerated bone loss. In premenopausal women
receiving endocrine therapy for breast cancer, changes in
bone mineral density have been observed with tamoxifen,
ovarian suppression, tamoxifen or aromatase inhibitors with
ovarian suppression, and oophorectomy.129–131 Thresholds for
pharmacologic intervention with bisphosphonates or RANK
ligand inhibitors include a history of osteoporosis, fragility
fractures, and osteopenia with additional risk factors. Several
studies have confirmed that antiresorptive therapies maintain
or increase bone mineral density in women or men treated
with endocrine therapy.129,132–137 While this is encouraging,
it remains unclear what impact these treatments have on the
incidence of fractures in those at risk.
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diagnostic mammography in addition to ultrasound with
uterine shielding.115 Fine needle aspiration may be difficult
to interpret in the setting of pregnancy-related proliferative
changes;116 core biopsy is preferred. The pathologist should
be alerted to the patient’s gravid state. Staging should be
directed by signs and symptoms and by clinical stage as for
the nonpregnant patient. Computed tomography, plain X-ray,
and nuclear medicine studies expose the fetus to radiation,
and so risks and benefits of this exposure need to be weighed.
Nuclear medicine studies are typically avoided due to a lack
of safety data, and breast MR, which requires gadolinium
contrast, is not safe during pregnancy.117,118
Surgery is often the safest mode of treatment during early
pregnancy as endocrine and cytotoxic therapies are contraindicated during the first trimester.119 For patients who undergo
surgery early in pregnancy and who do not need adjuvant chemotherapy, radiation may be delayed many months although
studies suggest worse outcomes with such delays.120 Fetal
radiation exposure is associated with birth defects, mental
retardation, childhood malignancy, and other complications,
and as the fetus grows its proximity to the breast increases, the
potential for fetal radiation exposure increases.119,121 Therefore,
radiation is contraindicated in the third trimester. Clinically
node-negative women undergo axillary staging with a sentinel
lymph node biopsy. Traditionally, radioisotope was avoided due
to the risk of radiation exposure to the fetus. More recent data
suggest that the dose to the fetus is small, and available data
suggest no negative impact on pregnancy outcomes with the
use of radioisotope.122,123 This method of sentinel node mapping
may be preferred due to continued concerns about teratogenicity or maternal anaphylaxis with methylene blue and isosulfan
blue dye, respectively, both of which are Pregnancy Class C
drugs. A small series, however, has not demonstrated negative
pregnancy outcomes with the use of blue dyes.123 The potential
risks and benefits of the sentinel node procedure need to be
discussed with patients preoperatively.
Fetal malformations are seen with first trimester exposure
to chemotherapy.124 Anthracycline-based regimens have the
most available data and can be given during the second and
third trimesters.125–127 Chemotherapy should be withheld
ideally at least 3 weeks before confinement to avoid cytopenias at the time of delivery. Other systemic therapies such
as endocrine therapy and trastuzumab are contraindicated
during pregnancy.128

Breast cancer in young women

Bone health
Young women with breast cancer are at higher risk of longterm side effects from cancer treatments and survivorship

Breast Cancer: Targets and Therapy 2016:8

Figure 2 Essential components of a survivorship plan.

submit your manuscript | www.dovepress.com

Dovepress

7

Ademuyiwa et al

Conclusion
Young patients with breast cancer face unique management challenges that are best addressed in a multidisciplinary setting. Currently, treatment recommendations
are made on tumor characteristics and not solely on age.
Close attention to long-term side effects with optimal
supportive care should be considered. A survivorship
care plan involving a multidisciplinary team is essential
for young patients (Figure 2). Younger patients are also
underrepresented in clinical trials and should be encouraged to participate for a better understanding of early-onset
breast cancer.

Acknowledgments
This publication was made possible by Grant Number
1K12CA167540 through the National Cancer Institute (NCI)
at the National Institutes for Health (NIH) and Grant Number UL1 TR000448 through the Clinical and Translational
Science Award (CTSA) program of the National Cancer for
Advancing Translational Sciences (NCATS) at the NIH. Its
contents, however, are solely the responsibility of the authors
and do not necessarily represent the official view of the NCI,
NCATS, or NIH.

Disclosure
The authors report no conflicts of interest in this work.

References

1. Bleyer A, Barr R, Hayes-Lattin B, et al. The distinctive biology
of cancer in adolescents and young adults. Nat Rev Cancer. 2008;
8(4):288–298.
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics
Review, 1975–2012. Bethesda, MD: National Cancer Institute; 2014.
Based on November 2014 SEER data submission, posted to the SEER
web site, April 2015. Available from: http://www.seer.cancer.gov/
csr/1975_2012/. Accessed November 12, 2015.
3. Smith RA, Saslow D, Sawyer KA, et al. American Cancer Society
guidelines for breast cancer screening: update 2003. CA Cancer J Clin.
2003;53(3):141–169.
4. Fancher TT, Palesty JA, Paszkowiak JJ, Kiran RP, Malkan AD,
Dudrick SJ. Can breast self-examination continue to be touted
justifiably as an optional practice? Int J Surg Oncol. 2011;2011:
965464.
5. Wilke LG, Broadwater G, Rabiner S, et al. Breast self-examination:
defining a cohort still in need. Am J Surg. 2009;198(4):575–579.
6. An YY, Kim SH, Kang BJ, Park CS, Jung NY, Kim JY. Breast cancer
in very young women (,30 years): correlation of imaging features with
clinicopathological features and immunohistochemical subtypes. Eur J
Radiol. 2015;84(10):1894–1902.
7. Goksu SS, Tastekin D, Arslan D, et al. Clinicopathologic features and
molecular subtypes of breast cancer in young women (age #35). Asian
Pac J Cancer Prev. 2014;15(16):6665–6668.
8. Checka CM, Chun JE, Schnabel FR, Lee J, Toth H. The relationship of
mammographic density and age: implications for breast cancer screening.
AJR Am J Roentgenol. 2012;198(3):W292–W295.

8

submit your manuscript | www.dovepress.com

Dovepress

Dovepress
9. Gilbert FJ, Tucker L, Gillan MG, et al. The TOMMY trial: a comparison
of TOMosynthesis with digital MammographY in the UK NHS Breast
Screening Programme – a multicentre retrospective reading study
comparing the diagnostic performance of digital breast tomosynthesis
and digital mammography with digital mammography alone. Health
Technol Assess. 2015;19(4): i–xxv, 1–136.
10. Zabicki K, Colbert JA, Dominguez FJ, et al. Breast cancer diagnosis in women 40 versus 50 to 60 years: increasing size and stage
disparity compared with older women over time. Ann Surg Oncol.
2006;13(8):1072–1077.
11. Partridge AH, Hughes ME, Ottesen RA, et al. The effect of age on
delay in diagnosis and stage of breast cancer. Oncologist. 2012;
17(6):775–782.
12. Partridge AH, Gelber S, Piccart-Gebhart MJ, et al. Effect of age on
breast cancer outcomes in women with human epidermal growth factor
receptor 2-positive breast cancer: results from a herceptin adjuvant trial.
J Clin Oncol. 2013;31(21):2692–2698.
13. Newell MS, D’Orsi C, Mahoney MC, et al. American College of Radiology ACR Appropriateness Criteria® Nonpalpable Mammographic
Findings (Excluding Calcifications) [cited August 17, 2015]. Available
from: http://www.acr.org/∼/media/ACR/Documents/AppCriteria/
Diagnostic/NonpalpableMammographicFindings.pdf. Accessed
November 12, 2015.
14. Harvey JA, Mahoney MC, Newell MS, et al. American College of
Radiology ACR Appropriateness Criteria® Palpable Breast Masses
[cited August 17, 2015]. Available from: http://www.acr.org/∼/media/
ACR/Documents/AppCriteria/Diagnostic/PalpableBreastMasses.pdf.
Accessed November 12, 2015.
15. Comstock CH, D’Orsi C, Bassett LW, et al. American College of
Radiology ACR Appropriateness Criteria® Breast Microcalcifications –
Initial Diagnostic Workup [cited August 17, 2015]. Available from:
http://www.acr.org/∼/media/ACR/Documents/AppCriteria/Diagnostic/
BreastMicrocalcifications.pdf. Accessed November 12, 2015.
16. Dershaw DD, D’Orsi C, Mahoney MC, et al. ACR Practice Parameter
for the Imaging Management of DCIS and Invasive Breast Carcinoma
[cited August 17, 2015]. Available from: http://www.acr.org/∼/media/
ACR/Documents/PGTS/guidelines/DCIS_Invasive_Breast_Carcinoma.
pdf. Accessed November 12, 2015.
17. Collaborative Group on Hormonal Factors in Breast Cancer. Familial
breast cancer: collaborative reanalysis of individual data from
52 epidemiological studies including 58,209 women with breast
cancer and 101,986 women without the disease. Lancet. 2001;
358(9291):1389–1399.
18. Dite GS, Jenkins MA, Southey MC, et al. Familial risks, early-onset
breast cancer, and BRCA1 and BRCA2 germline mutations. J Natl
Cancer Inst. 2003;95(6):448–457.
19. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and
heritable factors in the causation of cancer – analyses of cohorts of
twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;
343(2):78–85.
20. Peto J, Mack TM. High constant incidence in twins and other relatives
of women with breast cancer. Nat Genet. 2000;26(4):411–414.
21. Michailidou K, Holm NV, Verkasalo PK, et al. Genome-wide
association analysis of more than 120,000 individuals identifies 15
new susceptibility loci for breast cancer. Nat Genet. 2015;47(4):
373–380.
22. Michailidou K, Hall P, Gonzalez-Neira A, et al. Large-scale genotyping
identifies 41 new loci associated with breast cancer risk. Nat Genet.
2013;45(4):353–361, 361. e1–e2.
23. Lalloo F, Varley J, Moran A, et al. BRCA1, BRCA2 and TP53 mutations
in very early-onset breast cancer with associated risks to relatives. Eur
J Cancer. 2006;42(8):1143–1150.
24. Haffty BG, Choi DH, Goyal S, et al. Breast cancer in young
women (YBC): prevalence of BRCA1/2 mutations and risk of
secondary malignancies across diverse racial groups. Ann Oncol.
2009;20(10):1653–1659.

Breast Cancer: Targets and Therapy 2016:8

Dovepress
25. Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2
gene mutations in patients with early-onset breast cancer. J Natl Cancer
Inst. 1999;91(11):943–949.
26. Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast
cancer susceptibility genes among a large triple-negative breast cancer
cohort unselected for family history of breast cancer. J Clin Oncol.
2015;33(4):304–311.
27. Maxwell KN, Wubbenhorst B, D’Andrea K, et al. Prevalence of
mutations in a panel of breast cancer susceptibility genes in BRCA1/2negative patients with early-onset breast cancer. Genet Med. 2015;
17(8):630–638.
28. Easton DF, Pharoah PD, Antoniou AC, et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015;
372(23):2243–2257.
29. Copson E, Eccles B, Maishman T, et al. Prospective observational
study of breast cancer treatment outcomes for UK women aged
18–40 years at diagnosis: the POSH study. J Natl Cancer Inst. 2013;
105(13):978–988.
30. Keegan TH, DeRouen MC, Press DJ, Kurian AW, Clarke CA.
Occurrence of breast cancer subtypes in adolescent and young adult
women. Breast Cancer Res. 2012;14(2):R55.
31. Ahn SH, Son BH, Kim SW, et al. Poor outcome of hormone receptorpositive breast cancer at very young age is due to tamoxifen resistance:
nationwide survival data in Korea – a report from the Korean Breast
Cancer Society. J Clin Oncol. 2007;25(17):2360–2368.
32. Walker RA, Lees E, Webb MB, Dearing SJ. Breast carcinomas
occurring in young women (,35 years) are different. Br J Cancer.
1996;74(11):1796–1800.
33. Gonzalez-Angulo AM, Broglio K, Kau SW, et al. Women age 35
years with primary breast carcinoma: disease features at presentation.
Cancer. 2005;103(12):2466–2472.
34. Xiong Q, Valero V, Kau V, et al. Female patients with breast carcinoma
age 30 years and younger have a poor prognosis: the MD Anderson
Cancer Center experience. Cancer. 2001;92(10):2523–2528.
35. Sidoni A, Cavaliere A, Bellezza G, Scheibel M, Bucciarelli E. Breast
cancer in young women: clinicopathological features and biological
specificity. Breast. 2003;12(4):247–250.
36. Collins LC, Marotti JD, Gelber S, et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with
breast cancer. Breast Cancer Res Treat. 2012;131(3):1061–1066.
37. Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N,
Margenthaler JA. Elevated breast cancer mortality in women younger
than age 40 years compared with older women is attributed to
poorer survival in early-stage disease. J Am Coll Surg. 2009;208(3):
341–347.
38. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triplenegative breast cancer subtypes and preclinical models for selection of
targeted therapies. J Clin Invest. 2011;121(7):2750–2767.
39. Millis SZ, Gatalica Z, Winkler J, et al. Predictive biomarker profiling
of .6000 breast cancer patients shows heterogeneity in TNBC, with
treatment implications. Clin Breast Cancer. Epub 2015 Apr 28.
40. Traina TA, Miller K, Yardley DA, et al. Results from a phase 2 study
of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in
advanced AR+ triple-negative breast cancer (TNBC). Paper presented
at: American Society of Clinical Oncology Annual Meeting, May 29,
2015, Chicago, IL.
41. Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of
tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast
cancer trial in node-positive breast cancer comparing the addition of
docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG
02-98. J Clin Oncol. 2013;31(7):860–867.
42. Denkert C, von Minckwitz G, Brase JC, et al. Tumor-infiltrating
lymphocytes and response to neoadjuvant chemotherapy with or
without carboplatin in human epidermal growth factor receptor
2-positive and triple-negative primary breast cancers. J Clin Oncol.
2015;33(9):983–991.

Breast Cancer: Targets and Therapy 2016:8

Breast cancer in young women
43. Nanda R, Plimack ER, Dees EC, et al. A phase Ib multicohort study of
MK-3475 in patients with advanced solid tumors. Paper presented at:
American Society of Clinical Oncology, May 30, 2014, Chicago, IL.
44. Emens LA, Braiteh FS, Cassier P, et al. Inhibition of PD-L1 by
MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC). Paper presented at:
American Association for Cancer Research, April 18–22, 2015,
Pennsylvania, PA.
45. Azim HA Jr, Michiels S, Bedard PL, et al. Elucidating prognosis and
biology of breast cancer arising in young women using gene expression
profiling. Clin Cancer Res. 2012;18(5):1341–1351.
46. Anders CK, Hsu DS, Broadwater G, et al. Young age at diagnosis correlates
with worse prognosis and defines a subset of breast cancers with shared
patterns of gene expression. J Clin Oncol. 2008;26(20):3324–3330.
47. Ademuyiwa FO, Gao F, Hao L, et al. US breast cancer mortality
trends in young women according to race. Cancer. 2015;121(9):
1469–1476.
48. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA.
2006;295(21):2492–2502.
49. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive
analysis of estrogen receptor (ER)-negative, progesterone receptor
(PR)-negative, and HER2-negative invasive breast cancer, the so-called
triple-negative phenotype: a population-based study from the California
cancer Registry. Cancer. 2007;109(9):1721–1728.
50. Lund MJ, Trivers KF, Porter PL, et al. Race and triple negative threats
to breast cancer survival: a population-based study in Atlanta, GA.
Breast Cancer Res Treat. 2009;113(2):357–370.
51. Johnson RH, Chien FL, Bleyer A. Incidence of breast cancer with distant
involvement among women in the United States, 1976 to 2009. JAMA.
2013;309(8):800–805.
52. Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer
before age 40 years. Semin Oncol. 2009;36(3):237–249.
53. Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H.
Breast cancer in young women: poor survival despite intensive treatment. PLoS One. 2009;4(11):e7695.
54. Nixon AJ, Neuberg D, Hayes DF, et al. Relationship of patient
age to pathologic features of the tumor and prognosis for patients
with stage I or II breast cancer. J Clin Oncol. 1994;12(5):888–894.
55. Fowble BL, Schultz DJ, Overmoyer B, et al. The influence of young
age on outcome in early stage breast cancer. Int J Radiat Oncol Biol
Phys. 1994;30(1):23–33.
56. Han W, Kim SW, Park IA, et al. Young age: an independent risk factor
for disease-free survival in women with operable breast cancer. BMC
Cancer. 2004;4:82.
57. Han W, Kang SY; Korean Breast Cancer Soceity. Relationship between
age at diagnosis and outcome of premenopausal breast cancer: age less
than 35 years is a reasonable cut-off for defining young age-onset breast
cancer. Breast Cancer Res Treat. 2010;119(1):193–200.
58. Sheridan W, Scott T, Caroline S, et al. Breast cancer in young women:
have the prognostic implications of breast cancer subtypes changed over
time? Breast Cancer Res Treat. 2014;147(3):617–629.
59. Mahmood U, Morris C, Neuner G, et al. Similar survival with breast
conservation therapy or mastectomy in the management of young
women with early-stage breast cancer. Int J Radiat Oncol Biol Phys.
2012;83(5):1387–1393.
60. Kroman N, Holtveg H, Wohlfahrt J, et al. Effect of breast-conserving
therapy versus radical mastectomy on prognosis for young women with
breast carcinoma. Cancer. 2004;100(4):688–693.
61. Kurian AW, Lichtensztajn DY, Keegan TH, Nelson DO, Clarke CA,
Gomez SL. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California,
1998–2011. JAMA. 2014;312(9):902–914.
62. Portschy PR, Kuntz KM, Tuttle TM. Survival outcomes after contralateral prophylactic mastectomy: a decision analysis. J Natl Cancer Inst.
2014;106(8):duj160.

submit your manuscript | www.dovepress.com

Dovepress

9

Ademuyiwa et al
63. Mahmood U, Hanlon AL, Koshy M, et al. Increasing national mastectomy rates for the treatment of early stage breast cancer. Ann Surg
Oncol. 2013;20(5):1436–1443.
64. Didier F, Radice D, Gandini S, et al. Does nipple preservation in mastectomy
improve satisfaction with cosmetic results, psychological adjustment, body
image and sexuality? Breast Cancer Res Treat. 2009;118(3):623–633.
65. Metcalfe KA, Cil TD, Semple JL, et al. Long-term psychosocial
functioning in women with bilateral prophylactic mastectomy: does
preservation of the nipple-areolar complex make a difference? Ann
Surg Oncol. 2015;22(10):3324–3330.
66. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a
randomized trial comparing total mastectomy, lumpectomy, and
lumpectomy plus irradiation for the treatment of invasive breast cancer.
N Engl J Med. 2002;347(16):1233–1241.
67. Early Breast Cancer Trialists’ Collaborative Group; Darby S, McGale P,
Correa C, et al. Effect of radiotherapy after breast-conserving surgery
on 10-year recurrence and 15-year breast cancer death: meta-analysis
of individual patient data for 10,801 women in 17 randomised trials.
Lancet. 2011;378(9804):1707–1716.
68. NSABP Foundation Inc. Radiation therapy (WBI versus PBI) in treating women who have undergone surgery for ductal carcinoma in situ
or stage I or stage II breast cancer [cited August 30, 2015]. Available
from: https://clinicaltrials.gov/ct2/show/NCT00103181. NLM identifier: NCT00103181. Accessed November 12, 2015.
69. Shah C, Vicini F, Wazer DE, Arthur D, Patel RR, et al. The American
Brachytherapy Society consensus statement for accelerated partial
breast irradiation. Brachytherapy. 2013;12(4):267–277.
70. The American Society of Breast Surgeons consensus statement for
accelerated partial breast irradiation [cited August 30, 2015]. Available
from: https://www.breastsurgeons.org/statements/PDF_Statements/
APBI.pdf. Accessed November 12, 2015.
71. Smith BD, Arthur DW, Buchholz TA, et al. Accelerated partial
breast irradiation consensus statement from the American Society for
Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009;
74(4):987–1001.
72. Bartelink H, Maingon P, Poortmans P, et al. Whole-breast irradiation
with or without a boost for patients treated with breast-conserving
surgery for early breast cancer: 20-year follow-up of a randomised
phase 3 trial. Lancet Oncol. 2015;16(1):47–56.
73. Smith BD, Bentzen SM, Correa CR, et al. Fractionation for whole
breast irradiation: an American Society for Radiation Oncology
(ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys.
2011;81(1):59–68.
74. Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy
in high-risk postmenopausal breast-cancer patients given adjuvant
tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c
randomised trial. Lancet. 1999;353(9165):1641–1648.
75. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy
in high-risk premenopausal women with breast cancer who receive
adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b
Trial. N Engl J Med. 1997;337(14):949–955.
76. Ragaz J, livotto IA, Spinelli JJ, et al. Locoregional radiation therapy in
patients with high-risk breast cancer receiving adjuvant chemotherapy:
20-year results of the British Columbia randomized trial. J Natl Cancer
Inst. 2005;97(2):116–126.
77. Garg AK, Oh JL, Oswald MJ, et al. Effect of postmastectomy radiotherapy in patients ,35 years old with stage II-III breast cancer treated
with doxorubicin-based neoadjuvant chemotherapy and mastectomy.
Int J Radiat Oncol Biol Phys. 2007;69(5):1478–1483.
78. Wallgren A, Bonetti M, Gelber RD, et al. Risk factors for locoregional
recurrence among breast cancer patients: results from International
Breast Cancer Study Group Trials I through VII. J Clin Oncol.
2003;21(7):1205–1213.
79. Jagsi R, Raad RA, Goldberg S, et al. Locoregional recurrence rates
and prognostic factors for failure in node-negative patients treated with
mastectomy: implications for postmastectomy radiation. Int J Radiat
Oncol Biol Phys. 2005;62(4):1035–1039.

10

submit your manuscript | www.dovepress.com

Dovepress

Dovepress
80. Yildirim E, Berberoglu U. Can a subgroup of node-negative breast
carcinoma patients with T1-2 tumor who may benefit from postmastectomy radiotherapy be identified? Int J Radiat Oncol Biol Phys. 2007;
68(4):1024–1029.
81. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and
15-year survival: an overview of the randomised trials. Lancet. 2005;
365(9472):1687–1717.
82. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of
oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Lancet. 2013;381(9869):805–816.
83. Gray RG, Rea D, Handley K, et al. aTTom: Long-term effects
of continuing adjuvant tamoxifen to 10 years versus stopping at
5 years in 6,953 women with early breast cancer. J Clin Oncol.
2013;31:suppl;abstr 5.
84. Pagani O, O’Neill A, Castiglione M, et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer
patients with axillary node involvement: results of the International
Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer. 1998;
34(5):632–640.
85. International Breast Cancer Study Group; Colleoni M, Gelber S,
Goldhirsch A, et al. Tamoxifen after adjuvant chemotherapy for
premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol. 2006;
24(9):1332–1341.
86. Swain SM, Jeong JH, Wolmark N. Amenorrhea from breast cancer therapy – not a matter of dose. N Engl J Med. 2010;363(23):2268–2270.
87. Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):
436–446.
88. Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with
ovarian suppression in premenopausal breast cancer. N Engl J Med.
2014;371(2):107–118.
89. Bernhard J, Luo W, Ribi K, et al. Patient-reported outcomes with
adjuvant exemestane versus tamoxifen in premenopausal women with
early breast cancer undergoing ovarian suppression (TEXT and SOFT):
a combined analysis of two phase 3 randomised trials. Lancet Oncol.
2015;16(7):848–858.
90. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab
after adjuvant chemotherapy in HER2-positive breast cancer. N Engl
J Med. 2005;353(16):1659–1672.
91. Perez EA, Suman VJ, Davidson NE, et al. Sequential versus concurrent
trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol.
2011;29(34):4491–4497.
92. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant
chemotherapy for operable HER2-positive breast cancer. N Engl J Med.
2005;353(16):1673–1684.
93. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2positive breast cancer. N Engl J Med. 2011;365(14):1273–1283.
94. Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab
plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;
366(2):109–119.
95. Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab
in combination with standard neoadjuvant anthracycline-containing
and anthracycline-free chemotherapy regimens in patients with HER2positive early breast cancer: a randomized phase II cardiac safety study
(TRYPHAENA). Ann Oncol. 2013;24(9):2278–2284.
96. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced,
inflammatory, or early HER2-positive breast cancer (NeoSphere): a
randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;
13(1):25–32.
97. Christinat A, Pagani O. Fertility after breast cancer. Maturitas.
2012;73(3):191–196.
98. Rodriguez-Wallberg KA, Oktay K. Options on fertility preservation in
female cancer patients. Cancer Treat Rev. 2012;38(5):354–361.

Breast Cancer: Targets and Therapy 2016:8

Dovepress
99. Ronn R, Holzer HE. Oncofertility in Canada: the impact of cancer on
fertility. Curr Oncol. 2013;20(4):e338–e344.
100. Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal
women after adjuvant chemotherapy for breast cancer. J Clin Oncol.
2006;24(36):5769–5779.
101. Donnez J, Dolmans MM. Fertility preservation in women. Nat Rev
Endocrinol. 2013;9(12):735–749.
102. Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for
patients with cancer: American Society of Clinical Oncology clinical
practice guideline update. J Clin Oncol. 2013;31(19):2500–2510.
103. Friedler S, Koc O, Gidoni Y, Raziel A, Ron-El R. Ovarian response
to stimulation for fertility preservation in women with malignant
disease: a systematic review and meta-analysis. Fertil Steril. 2012;
97(1):125–133.
104. Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med.
2015;372(10):923–932.
105. Azim HA Jr, Santoro L, Pavlidis N, et al. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J
Cancer. 2011;47(1):74–83.
106. Azim HA Jr, Kroman N, Paesmans M, et al. Prognostic impact of
pregnancy after breast cancer according to estrogen receptor status:
a multicenter retrospective study. J Clin Oncol. 2013;31(1):
73–79.
107. Kroman N, Jensen MB, Wohlfahrt J, Ejlertsen B; Danish Breast Cancer
Cooperative Group. Pregnancy after treatment of breast cancer – a
population-based study on behalf of Danish Breast Cancer Cooperative Group. Acta Oncol. 2008;47(4):545–549.
108. Valachis A, Tsali L, Pesce LL, et al. Safety of pregnancy after primary
breast carcinoma in young women: a meta-analysis to overcome
bias of healthy mother effect studies. Obstet Gynecol Surv. 2010;
65(12):786–793.
109. International Breast Cancer Study Group. Pregnancy Outcome and
Safety of Interrupting Therapy for Women With Endocrine Responsive
Breast Cancer (POSITIVE) [cited August 17, 2015]. Available from:
https://clinicaltrials.gov/ct2/show/NCT02308085?term=02308085&ra
nk=1. NLM identifier: NCT02308085. Accessed November 12, 2015.
110. Pagani O, Azim H Jr. Pregnancy after breast cancer: myths and facts.
Breast Care (Basel). 2012;7(3):210–214.
111. Azim HA Jr, Metzger-Filho O, de Azambuja E, et al. Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in
the HERA trial (BIG 01-01). Breast Cancer Res Treat. 2012;133(1):
387–391.
112. Saunders CM, Baum M. Breast cancer and pregnancy: a review. J R
Soc Med. 1993;86(3):162–165.
113. Anderson JM. Mammary cancers and pregnancy. Br Med J.
1979;1(6171):1124–1127.
114. Noyes RD, Spanos WJ Jr, Montague ED. Breast cancer in women
aged 30 and under. Cancer. 1982;49(6):1302–1307.
115. Vashi R, Hooley R, Butler R, Geisel J, Philpotts L. Breast imaging of the pregnant and lactating patient: imaging modalities and
pregnancy-associated breast cancer. AJR Am J Roentgenol. 2013;
200(2):321–328.
116. Heymann JJ, Halligan AM, Hoda SA, Facey KE, Hoda RS. Fine needle
aspiration of breast masses in pregnant and lactating women: experience with 28 cases emphasizing Thinprep findings. Diagn Cytopathol.
2015;43(3):188–194.
117. ACOG Committee on Obstetric Practice. ACOG Committee Opinion.
Number 299, September 2004 (replaces No 158, September 1995).
Guidelines for diagnostic imaging during pregnancy. Obstet Gynecol.
2004;104(3):647–651.
118. Bural GG, Laymon CM, Mountz JM. Nuclear imaging of a pregnant
patient: should we perform nuclear medicine procedures during pregnancy? Mol Imaging Radionucl Ther. 2012;21(1):1–5.
119. Toesca A, Gentilini O, Peccatori F, Azim HA Jr, Amant F.
Locoregional treatment of breast cancer during pregnancy. Gynecol
Surg. 2014;11(4):279–284.

Breast Cancer: Targets and Therapy 2016:8

Breast cancer in young women
120. Chen Z, King W, Pearcey R, Kerba M, Mackillop WJ. The relationship between waiting time for radiotherapy and clinical outcomes:
a systematic review of the literature. Radiother Oncol. 2008;87(1):
3–16.
121. Mazonakis M, Varveris H, Damilakis J, Theoharopoulos N,
Gourtsoyiannis N. Radiation dose to conceptus resulting from tangential breast irradiation. Int J Radiat Oncol Biol Phys. 2003;55(2):
386–391.
122. Gentilini O, Cremonesi M, Toesca A, et al. Sentinel lymph node biopsy
in pregnant patients with breast cancer. Eur J Nucl Med Mol Imaging.
2010;37(1):78–83.
123. Gropper AB, Calvillo KZ, Dominici L, et al. Sentinel lymph node
biopsy in pregnant women with breast cancer. Ann Surg Oncol.
2014;21(8):2506–2511.
124. Ring AE, Smith IE, Jones A, Shannon C, Galani E, Ellis PA.
Chemotherapy for breast cancer during pregnancy: an 18-year
experience from five London teaching hospitals. J Clin Oncol. 2005;
23(18):4192–4197.
125. Hahn KM, Johnson PH, Gordon N, et al. Treatment of pregnant breast
cancer patients and outcomes of children exposed to chemotherapy in
utero. Cancer. 2006;107(6):1219–1226.
126. Berry DL, Theriault RL, Holmes FA, et al. Management of breast
cancer during pregnancy using a standardized protocol. J Clin Oncol.
1999;17(3):855–861.
127. Murthy RK, Theriault RL, Barnett CM, et al. Outcomes of children
exposed in utero to chemotherapy for breast cancer. Breast Cancer
Res. 2014;16(6):500.
128. Zagouri F, Sergentanis TN, Chrysikos D, Papadimitriou CA,
Dimopoulos MA, Bartsch R. Trastuzumab administration during
pregnancy: a systematic review and meta-analysis. Breast Cancer
Res Treat. 2013;137(2):349–357.
129. Shapiro CL, Halabi S, Hars V, et al. Zoledronic acid preserves bone
mineral density in premenopausal women who develop ovarian failure
due to adjuvant chemotherapy: final results from CALGB trial 79809.
Eur J Cancer. 2011;47(5):683–689.
130. Sverrisdottir A, Fornander T, Jacobsson H, von Schoultz E, Rutqvist LE.
Bone mineral density among premenopausal women with early
breast cancer in a randomized trial of adjuvant endocrine therapy.
J Clin Oncol. 2004;22(18):3694–3699.
131. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant
endocrine therapy plus zoledronic acid in premenopausal women
with early-stage breast cancer: 5-year follow-up of the ABCSG-12
bone-mineral density substudy. Lancet Oncol. 2008;9(9):840–849.
132. Brufsky AM, Harker WG, Beck JT, et al. Final 5-year results of
Z-FAST trial: adjuvant zoledronic acid maintains bone mass in
postmenopausal breast cancer patients receiving letrozole. Cancer.
2012;118(5):1192–1201.
133. Smith MR, Egerdie B, Hernández Toriz N, et al. Denosumab in men
receiving androgen-deprivation therapy for prostate cancer. N Engl J
Med. 2009;361(8):745–755.
134. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of
denosumab in patients receiving adjuvant aromatase inhibitors for
nonmetastatic breast cancer. J Clin Oncol. 2008;26(30):4875–4882.
135. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic
acid prevents cancer treatment-induced bone loss in premenopausal
women receiving adjuvant endocrine therapy for hormone-responsive
breast cancer: a report from the Austrian Breast and Colorectal Cancer
Study Group. J Clin Oncol. 2007;25(7):820–828.
136. Coleman R, Cameron D, Dodwell D, et al. Adjuvant zoledronic acid
in patients with early breast cancer: final efficacy analysis of the
AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet
Oncol. 2014;15(9):997–1006.
137. Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast
cancer (ABCSG-18): a multicentre, randomised, double-blind,
placebo-controlled trial. Lancet. 2015;386(9992):433–443.
138. American Cancer Society. Breast Cancer Facts and Figures 2015–2016.
Atlanta, CA: American Cancer Society; 2015.

submit your manuscript | www.dovepress.com

Dovepress

11

Dovepress

Ademuyiwa et al

Dovepress

Breast Cancer: Targets and Therapy

Publish your work in this journal
Breast Cancer: Targets and Therapy is an international, peerreviewed open access journal focusing on breast cancer research,
identification of therapeutic targets and the optimal use of preventative and integrated treatment interventions to achieve improved
outcomes, enhanced survival and quality of life for the cancer patient.

View the full aims and scopes of this journal here. The manuscript
management system is completely online and includes a very quick
and fair peer-review system, which is all easy to use. Visit http://
www.dovepress.com/testimonials.php to read real quotes from
published authors.

Submit your manuscript here: http://www.dovepress.com/breast-cancer---targets-and-therapy-journal

12

submit your manuscript | www.dovepress.com

Dovepress

Breast Cancer: Targets and Therapy 2016:8

